研究单位：[1]Peking Union Medical College Hospital[2]Peking Union Medical College Hospital,Beijing,Beijing,China,100730[3]Beijing Shunyi Hospital,Beijing,Beijing,China,101300[4]Fujian Medical University Union Hospital,Fuzhou,Fujian,China,350001[5]The Third Affiliated Hospital of Guangzhou Medical University,Guangzhou,Guangdong,China,510150[6]Shenzhen People''s Hospital,Shenzhen,Guangdong,China,518020[7]The Second People''s Hospital of Shenzhen,Shenzhen,Guangdong,China,518035[8]The First Affiliated Hospital of Guangxi Medical University,Nanning,Guangxi,China,530021[9]The Affilicated Hospital of Inner Mongolia Medical University,Hohhot,Inner Mongolia,China,010110[10]Jiangsu Province Hospital,Nanjing,Jiangsu,China,210029[11]The Second Affiliated Hospical of Nanchang University,Nanchang,Jiangxi,China,330006[12]The Second Affiliated Hospital of Dalian Medical University,Dalian,Liaoning,China,116031[13]The First Hospital of China Medical University,Shenyang,Liaoning,China,110001[14]Qilu Hospital of Shandong University,Jinan,Shandong,China,250012[15]Ruijin Hospital, Shanghai Jiaotong University School of Medicine,Shanghai,Shanghai,China,200025[16]Tianjin Medical University Genral Hospital,Tianjin,Tianjin,China,300052[17]First Affiliated Hospital of Kunming Medical University,Kunming,Yunnan,China,650032[18]First People''s Hospital of Yunnan Province,Kunming,Yunnan,China,650032[19]The Second Affiliated Hospital Zhejiang University School of Medicine,Hangzhou,Zhejiang,China,311202
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by thrombosis and pregnancy morbidity in patients with persistently positive antiphospholipid antibodies (aPLs). However, large-scale research on general population with persistent aPLs has been lacking. This project proposes to establish the first multicenter cohort of patients with persistently positive aPLs in China and conduct a comprehensive clinical phenotyping study. Based on traditional phenotypes of thrombotic and pregnancy events, the focus will be on extra-standard clinical phenotypes and prospective assessment of event risk and prognosis in aPL-positive population. A prospective analysis of extra-standard antibodies will also be conducted to recommend detection criteria for extra-standard antibody application in China and to assess their clinical significance.
